Thomaspartners Increased Jpmorgan Chase & Co (JPM) Stake, Catalina Lighting (CALA) Has 1.2 Sentiment

July 27, 2017 - By Stephen Andrade

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $549.71 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Thomaspartners Inc increased Jpmorgan Chase & Co (JPM) stake by 2.95% reported in 2016Q4 SEC filing. Thomaspartners Inc acquired 71,748 shares as Jpmorgan Chase & Co (JPM)’s stock declined 6.04%. The Thomaspartners Inc holds 2.50M shares with $215.86M value, up from 2.43M last quarter. Jpmorgan Chase & Co now has $326.15B valuation. The stock declined 0.14% or $0.13 reaching $91.8 on the news. About 5.92 million shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since July 27, 2016 and is uptrending. It has outperformed by 17.04% the S&P500.

Among 29 analysts covering JPMorgan Chase & Co (NYSE:JPM), 16 have Buy rating, 2 Sell and 11 Hold. Therefore 55% are positive. JPMorgan Chase & Co had 65 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Nomura with “Neutral” on Thursday, April 14. The rating was downgraded by Macquarie Research to “Neutral” on Friday, September 9. The stock of JPMorgan Chase & Co. (NYSE:JPM) earned “Neutral” rating by Goldman Sachs on Monday, January 11. The rating was maintained by Goldman Sachs with “Neutral” on Thursday, April 14. The company was maintained on Monday, October 5 by Citigroup. The firm has “Neutral” rating given on Friday, January 15 by UBS. The rating was maintained by Argus Research on Monday, January 18 with “Buy”. The company was maintained on Thursday, July 20 by Oppenheimer. Jefferies maintained JPMorgan Chase & Co. (NYSE:JPM) rating on Tuesday, July 21. Jefferies has “Buy” rating and $78 target. The firm earned “Buy” rating on Wednesday, January 11 by UBS.

Investors sentiment decreased to 0.82 in 2016 Q4. Its down 0.15, from 0.97 in 2016Q3. It fall, as 69 investors sold JPM shares while 807 reduced holdings. 166 funds opened positions while 553 raised stakes. 2.60 billion shares or 2.27% more from 2.54 billion shares in 2016Q3 were reported. Camelot Portfolios Lc invested in 0.22% or 4,930 shares. Synovus Fin invested 0.57% in JPMorgan Chase & Co. (NYSE:JPM). Alpine Prns Vi Ltd Company has 23,319 shares for 0.94% of their portfolio. 187,738 are held by Busey. Oak Associates Ltd Oh has invested 3.3% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Natl Asset Mngmt Inc holds 0.84% or 48,038 shares in its portfolio. 1St Source Bancorp holds 113,807 shares. Mississippi-based Trustmark Bank Tru Department has invested 0.22% in JPMorgan Chase & Co. (NYSE:JPM). Burgundy Asset Limited has 0.02% invested in JPMorgan Chase & Co. (NYSE:JPM). Wedgewood Invsts Pa has invested 0.25% in JPMorgan Chase & Co. (NYSE:JPM). Amica Retiree holds 2% in JPMorgan Chase & Co. (NYSE:JPM) or 29,145 shares. Essex Fincl Svcs Incorporated has 75,510 shares. Argi Service holds 11,398 shares. Boltwood Cap Management has 1.69% invested in JPMorgan Chase & Co. (NYSE:JPM). Hourglass Cap Limited Liability Corp invested 0.07% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM).

Since May 11, 2017, it had 0 insider purchases, and 1 insider sale for $568,100 activity. BACON ASHLEY sold 6,514 shares worth $568,100.

Analysts await Calithera Biosciences Inc (NASDAQ:CALA) to report earnings on August, 8. They expect $-0.29 EPS, up 47.27% or $0.26 from last year’s $-0.55 per share. After $-0.22 actual EPS reported by Calithera Biosciences Inc for the previous quarter, Wall Street now forecasts 31.82% negative EPS growth.

Franklin Street Advisors Inc Nc holds 0.07% of its portfolio in Calithera Biosciences Inc for 124,580 shares. Adage Capital Partners Gp L.L.C. owns 3.64 million shares or 0.03% of their US portfolio. Moreover, Tfs Capital Llc has 0.02% invested in the company for 28,408 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. Oxford Asset Management, a United Kingdom-based fund reported 49,490 shares.

Ratings analysis reveals 50% of Calithera Biosciences’s analysts are positive. Out of 2 Wall Street analysts rating Calithera Biosciences, 1 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. CALA was included in 2 notes of analysts from October 25, 2016. The firm earned “Sell” rating on Tuesday, October 25 by Citigroup. On Thursday, January 5 the stock rating was initiated by H.C. Wainwright with “Buy”.

About 236,942 shares traded. Calithera Biosciences Inc (CALA) has risen 278.82% since July 27, 2016 and is uptrending. It has outperformed by 262.12% the S&P500.